Publications

• Improving Outcomes of Acute Promyelocytic Leukemia in the Current Era: Analysis of the SEER Database.

  (Guru Murthy GS, Szabo A, Michaelis L, Carlson KS, Runaas L, Abedin S, Atallah E.) J Natl Compr Canc Netw. 2020 02;18(2):169-175 PMID: 32023530 SCOPUS ID: 2-s2.0-85079065513 02/06/2020

• Contemporary Outcomes for Advanced-Stage Classical Hodgkin Lymphoma in the U.S.: Analysis of Surveillance, Epidemiology, and End Results Database.

  (Guru Murthy GS, Szabo A, Hamadani M, Fenske TS, Shah NN.) Oncologist. 2019 11;24(11):1488-1495 PMID: 31467178 PMCID: PMC6853108 SCOPUS ID: 2-s2.0-85071466837 08/31/2019

• Transformation of a non-secretory neuroendocrine tumor to insulinoma after treatment with Sunitinib: A case report and review of the literature.

  (Clover T, Abdelkader A, Guru Murthy GS.) J Oncol Pharm Pract. 2019 Sep;25(6):1516-1519 PMID: 30089432 SCOPUS ID: 2-s2.0-85052579205 08/10/2018

• Incidence and survival of T-cell acute lymphoblastic leukemia in the United States.

  (Guru Murthy GS, Pondaiah SK, Abedin S, Atallah E.) Leuk Lymphoma. 2019 05;60(5):1171-1178 PMID: 30407885 SCOPUS ID: 2-s2.0-85057299329 11/09/2018

• Outcomes of Reduced-Intensity Conditioning Allogeneic Hematopoietic Cell Transplantation Performed in the Inpatient versus Outpatient Setting.

  (Guru Murthy GS, Hari PN, Szabo A, Pasquini M, Narra R, Khan M, Abedin S, Chhabra S, Dhakal B, D'Souza A, Drobyski WR, Rizzo JD, Runaas L, Shah NN, Shaw B, Saber W, Fenske T, Hamadani M.) Biol Blood Marrow Transplant. 2019 04;25(4):827-833 PMID: 30572109 SCOPUS ID: 2-s2.0-85059680507 12/21/2018

• Myeloid malignancies after treatment for solid tumours.

  (Guru Murthy GS, Abedin S.) Best Pract Res Clin Haematol. 2019 03;32(1):40-46 PMID: 30927974 SCOPUS ID: 2-s2.0-85062663467 04/01/2019

• Treatment-Free Remission in CML: the US Perspective.

  (Guru Murthy GS, Atallah E.) Curr Hematol Malig Rep. 2019 02;14(1):56-61 PMID: 30645715 SCOPUS ID: 2-s2.0-85060169494 01/16/2019

• Epidemiology and survival of blastic plasmacytoid dendritic cell neoplasm.

  (Guru Murthy GS, Pemmaraju N, Atallah E.) Leuk Res. 2018 10;73:21-23 PMID: 30189324 SCOPUS ID: 2-s2.0-85052637608 09/07/2018

• Incidence and survival of therapy related myeloid neoplasm in United States.

  (Guru Murthy GS, Hamadani M, Dhakal B, Hari P, Atallah E.) Leuk Res. 2018 08;71:95-99 PMID: 30048839 SCOPUS ID: 2-s2.0-85050226100 07/27/2018

• Recipient Immune Modulation with Atorvastatin for Acute Graft-versus-Host Disease Prophylaxis after Allogeneic Transplantation.

  (Kanate AS, Hari PN, Pasquini MC, Visotcky A, Ahn KW, Boyd J, Guru Murthy GS, Rizzo JD, Saber W, Drobyski W, Michaelis L, Atallah E, Carlson KS, D'Souza A, Fenske TS, Cumpston A, Bunner P, Craig M, Horowitz MM, Hamadani M.) Biol Blood Marrow Transplant. 2017 Aug;23(8):1295-1302 PMID: 28412518 SCOPUS ID: 2-s2.0-85019639994 04/17/2017

• Relapse of Hodgkin lymphoma after autologous transplantation: Time to rethink treatment?

  (Jethava Y, Guru Murthy GS, Hamadani M.) Hematol Oncol Stem Cell Ther. 2017 Jun;10(2):47-56 PMID: 28183681 SCOPUS ID: 2-s2.0-85012253423 02/12/2017

• Systemic Anaplastic Lymphoma Kinase-positive Anaplastic Large Cell Lymphoma: A Population-based Analysis of Incidence and Survival.

  (Guru Murthy GS, Hamadani M, Bhatt VR, Dhakal I, Mehta P.) Clin Lymphoma Myeloma Leuk. 2017 04;17(4):201-206 PMID: 28395812 SCOPUS ID: 2-s2.0-85017190298 04/12/2017